Genechem Inc. has created conjugates comprising gemcitabine covalently linked to sialyllactose through a linker and reported to be useful for the treatment of cancer.
Medipol Ueniversitesi Zonguldak Buelent Ecevit University has patented new specific arylidene barbiturate derivatives reported to be useful for the treatment of cancer.
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has described new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast and prostate cancer.
The U.S. Patent and Trademark Office has provided updated guidance on the question of patent subject matter eligibility for inventions that rely on artificial intelligence, stating that a patent claim that does little more than recite an abstract idea is not subject-matter eligible.
A joint Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. patent details NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
Work at Intra-Cellular Therapies Inc. has led to the identification of heterocycle fused gamma-carbolines characterized as 5-HT2A receptor ligands reported to be useful for the treatment of neurological disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized new benzimidazole derivatives acting as serine/threonine-protein kinase SIK inhibitors.